Gsk Share Discussion Threads

[freds13] 21/5/2007 23:40

USA CLOSE
GLAXOSMITHKLINE PLC (NYSE:GSK)
After Hours: 53.00 Down 0.18 (0.34%) as of 6:47PM ET on 05/21/07
Last Trade: 53.18
Trade Time: 4:00PM ET
Change: Down 4.53 (7.85%)
Prev Close: 57.71
Open: 57.66
Bid: N/A
Ask: N/A
1y Target Est: 62.25

Day's Range: 52.55 - 57.70
52wk Range: 51.18 - 59.98
Volume: 13,646,179
Avg Vol (3m): 1,472,080
Market Cap: 148.37B
P/E (ttm): 14.18
EPS (ttm): 3.75
Div & Yield: 1.92 (3.40%)
Even down after hours in the U.S. - could turn around if the company are to be believed.

[freds13] 21/5/2007 23:39

USA CLOSE
GLAXOSMITHKLINE PLC (NYSE:GSK)
After Hours: 53.00 Down 0.18 (0.34%) as of 6:47PM ET on 05/21/07
Last Trade: 53.18
Trade Time: 4:00PM ET
Change: Down 4.53 (7.85%)
Prev Close: 57.71
Open: 57.66
Bid: N/A
Ask: N/A
1y Target Est: 62.25

Day's Range: 52.55 - 57.70
52wk Range: 51.18 - 59.98
Volume: 13,646,179
Avg Vol (3m): 1,472,080
Market Cap: 148.37B
P/E (ttm): 14.18
EPS (ttm): 3.75
Div & Yield: 1.92 (3.40%)
Even down after hours in the U.S. - could turn around if the company are to be believed.

[freds13] 21/5/2007 23:36

Frankg - lol - that`s what I call a mistake! Glad I spotted it b4 anyone else.

[montyhedge] 21/5/2007 20:10

Dowm 8% in the states.

[jonak] 21/5/2007 19:46

Spitzer is a white collar blackmailer - usual method of operation is to fabricate a plausible class action suit against a large corporation, threaten a lawsuit and bad publicity, and then settle out court. He pockets around 40% of any settlement - its a very lucrative business for him. Anything he has been involved with is likely to be malicious in intent and erroneous in content. Selective presentation and interpretation of data to further his cause, regardless of truth or justice. I hope GSK will continue to promote a rigourous and scientific interpretation of the clinical trials data.

[frankg] 21/5/2007 19:28

freds13 - 21 May'07 - 16:45 - 22 of 24

"I MEAN £3BILLION "


ROFL - easy mistake...... Still ROFL ..... !!

[miata] 21/5/2007 16:19

The study will be published this week in the New England Journal of Medicine.

[accumulator] 21/5/2007 16:13

don't know why but i can't find the same article on the New England Journal of Medicine.

[freds13] 21/5/2007 15:45

I MEAN £3BILLION

[freds13] 21/5/2007 15:43

Pharmaceuticals
Glaxo's Drug Disaster?
Matthew Herper, 05.21.07, 11:15 AM ET

Glaxo's Faustian Pill
Diabetes Drug Cuts Heart Attacks
Cancer Worries Dog New Anti-Fat Drugs
Attacking Heart Attacks

The biggest-selling diabetes drug in the world dramatically increases the risk of heart attacks and death from heart problems, according to an analysis by a top cardiologist published online in The New England Journal of Medicine.

Millions of patients have been prescribed the pill, Avandia, since it was introduced eight years ago. Drug maker GlaxoSmithKline (nyse: GSK - news - people ) stands to lose much of the $3 billion it makes annually on the pill if the criticisms prove true. Heart attacks are the leading cause of death in patients with diabetes. Rival Actos, from Japanese drug maker Takeda, does not seem to cause heart attacks and may prevent them.

If Avandia does boost heart risk, the repercussions will reach far beyond GlaxoSmithKline or even the patients who may have been harmed by the drug. Right now both houses of Congress are debating bills that would reform the U.S. Food and Drug Administration; these bills must be passed by September or the FDA will have inadequate funds.

A drug safety scandal could reignite the congressional debate, putting Big Pharma back on the defensive. Some of the toughest reforms, like a proposal to create a separate FDA office that would track side effects and yank products from the market, have fallen by the wayside.

Steven Nissen, chairman of cardiology at the Cleveland Clinic, performed the analysis by combing through 42 already completed studies of Avandia. Nissen has become one of the most prominent drug safety advocates in the U.S. since he warned in 2001 that Merck's (nyse: MRK - news - people ) painkiller Vioxx caused heart problems. Vioxx was pulled from the market three years later.

Nissen began to worry about Avandia last September when he saw the results of a 5,000-patient clinical trial, called DREAM, that showed Avandia prevented diabetes. Despite this benefit, patients on Avandia were 37% more likely to have heart problems, although the result was not statistically significant.

The DREAM results were "very troubling," Nissen told Forbes.com at the time (see: "Glaxo's Faustian Pill"). In a December letter to The Lancet, the medical journal that published DREAM, he went further, saying the result raised "serious questions about the safety of this agent." Also in December, he became more troubled when another study, meant to show that Avandia worked better than either of two cheaper generic diabetes drugs, also pointed to increased heart problems.

But putting together all of the data proved difficult. With his Vioxx work, Nissen was able to use data that had been presented at an FDA meeting. This time, he had to find studies that had been conducted by Glaxo after Avandia was approved.

Through a Google (nasdaq: GOOG - news - people ) search, Nissen found a Web site put up by Glaxo that contained results from all of its clinical trials. The site had been created as a result of a settlement with former New York Attorney General Elliot Spitzer. He found the 42 studies, and he and statistician Kathy Wolski did the analysis and wrote the paper in a matter of days.

In an editorial in the New England Journal, two other veterans of the Vioxx controversy--Bruce Psaty of the University of Washington and Curt Furberg of Wake Forest University--write that there is no clear reason to prescribe Avandia at all now. They call for the FDA to take action and complain that bigger and better studies of the drug should have been completed earlier.

Nissen is doing a study of Actos for Takeda and consults for most major pharmaceutical firms, but he gives all the fees drug makers send him to charity.

Analyses like the one Nissen conducted are fraught with weaknesses; combining data from different studies creates all kinds of statistical problems. But they have become one of the main ways of raising concerns about risky medical drugs and devices.

Before Vioxx, such combined studies raised concerns about links between common antidepressants and suicidal thoughts. Later, combined data from different studies prevented Pargluva, a medicine from Bristol-Myers Squibb (nyse: BMY - news - people ) that was meant to work in a way similar to Avandia, from being approved, also because of heart risks.

More recently, data re-analysis started the debate about the safety of the drug-coated stents made by Johnson & Johnson (nyse: JNJ - news - people ) and Boston Scientific (nyse: BSX - news - people ), and led the FDA to force Zelnorm, a constipation drug from Novartis (nyse: NVS - news - people ), off the market.

One key measure of reform bills in Congress is that they would give the FDA more money to conduct these kinds of analyses. Another, major part of the Senate bill would force companies to make all study results public, making it easier for researchers like Nissen to conduct their own analyses.

If Avandia is a risky drug, there is perhaps a dark irony to its story. Avandia was invented in the laboratories of Smithkline Beecham, a Glaxo predecessor, two decades ago as one of a class of medicines meant to treat diabetes. But a rival drug, Rezulin, from Pfizer (nyse: PFE - news - people ), beat it to market in 1997.

The FDA may have felt pressure to approve Avandia two years later because safety problems were starting to show up with Rezulin. The Pfizer drug was pulled from the market in 2000 because it caused liver problems.

The FDA and Glaxo were unable to comment in time for this story.
$3 a year could be lost!

[dope007] 21/5/2007 15:39

yes PE around 14 but will see what this reports actally means if that was the reason for the panic dumping of stock.

Looks like a few leveraged longs got savaged by leveraged short selling on the report if that was the reason.

[freds13] 21/5/2007 15:38

USA LATEST :
Market View
GSK (GlaxoSmithKline )
Last: 1,426.00p
Change: -38.00 (-2.60%)
Revenue (ttm): £23,225.0M
EPS: 0.95
Market Cap: £83,071.13M
Time: 11:22am ET

[freds13] 21/5/2007 15:32

Could be a very good buying oppo. soon - or not?

[maiseymouse] 15/5/2007 11:54

report on the market insider of some interest in glaxo

[therev] 15/5/2007 11:16

LONDON (SHARECAST) - GlaxoSmithKline was stronger Tuesday as Goldman Sachs upgraded shares in the drugs major to 'neutral' from 'sell' with price target up to 1,500p from 1,425p previously.

The broker said it was removing Glaxo from its Sell List as it sees greater potential for sector-relative price underperformance elsewhere.

Goldman also predicts better times for diabetes drug Avandia this year and US approval for cervical cancer vaccine Cervarix at the end of the third quarter.

[freds13] 11/5/2007 23:46

USA CLOSE GLAXOSMITHKLINE PLC (NYSE:GSK)
After Hours: 56.50 Down 0.31 (0.54%) as of 5:23pm ET on 05/11/07
Last Trade: 56.81
Trade Time: 4:00PM ET
Change: Up 0.39 (0.69%)
Prev Close: 56.42
Open: 56.41
Bid: N/A
Ask: N/A
1y Target Est: 63.40

Day's Range: 56.32 - 56.85
52wk Range: 51.18 - 59.98
Volume: 1,106,600
Avg Vol (3m): 1,585,650
Market Cap: 158.50B
P/E (ttm): 15.03
EPS (ttm): 3.78
Div & Yield: 1.92 (3.40%)
Pity about the After Hours!

[diku] 11/5/2007 22:11

Dope007

Noticed that as well...

[dope007] 09/5/2007 09:23

Gateside I think a small minority of the stock market is causing a narrow rally that is unsustainable imho.

[dougcsv] 02/5/2007 15:48

XD perhaps ?

[gateside] 02/5/2007 15:04

Someone remind Glaxo that the Stock Market is going UP!!!

[gucci] 02/5/2007 11:55

heading down fo 1380p i wonder?

[chrissingh] 01/5/2007 13:55

Why is it dropping after the news of Veramyst approval? Should be rising!

[gateside] 30/4/2007 06:31

GlaxoSmithKline said it has received approval from the US FDA for its Veramyst nasal spray.

In the clinical trials, the company said Veramyst was effective for relieving overall nasal allergy symptoms, and demonstrated consistent and significant improvement in relieving overall allergic eye symptoms.

This is the first regulatory approval of Veramyst, which is currently under regulatory review under the trade name Allermist in Japan and under the tradename Avamys in Europe, Canada, Australia and other international markets.

Veramyst will be available by prescription in the US by late May, it added.

[gateside] 26/4/2007 06:58

The Investment Column: Profits dip at GSK but the pipeline is set to deliver
Edited by Andrew Dewson
Published: 26 April 2007

Our view: Buy

Share price: 1,464p

GlaxoSmithKline looks good value thanks to its healthy long-term pipeline and significant discount to its peers. Europe's largest pharmaceutical company unveiled first-quarter results yesterday, but profits dipped after sales took a hit due to the strength of the pound and the loss of patent protection on a couple of key medicines. Pre-tax profits in the three months to 31 March came in at £2.14bn, a drop of 1 per cent, on sales down 4 per cent at £5.59bn.

However, GSK has a strong pipeline with 158 products in development. Furthermore, 2007 looks likely to be an important year for the group with five key products hitting the market all with blockbuster potential. Its breast cancer drug Tykerb was given the green light in the US in March while cervical cancer vaccine Cervarix should be approved later this year. Both products are central to Glaxo's expanded presence in the oncology field.

Analysts at Deutsche Bank believe that Coreg, a cardiovascular treatment launched in the US in March, is an undervalued asset. Deutsche is forecasting sales for Coreg, which is a once-daily pill to treat hypertension and heart failure, of £1.3bn by 2012.

Although GSK was one of the worst FTSE 100 performers last year, hit by generic competition and a slowdown in growth with its two best-sellers, chief executive JP Garnier has done much to bring new drugs on stream. Yesterday's numbers may disappoint some observers, but the future looks brighter and Mr Garnier's successor, should inherit a company on the up.

BUY